Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, rhinitis, atopic dermatitis, and anaphylaxis; inflammatory diseases such as rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases.
Type:
Grant
Filed:
April 30, 2020
Date of Patent:
December 6, 2022
Assignee:
EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
Abstract: A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
November 29, 2022
Assignees:
Merck Sharp & Dohme LLC, Adimab LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
November 22, 2022
Assignee:
CSL Limited
Inventors:
Malgorzata Wygrecka, Marc Nolte, Con Panousis
Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
November 15, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
Abstract: Infection with obligatory intracellular bacteria is difficult to treat as intracellular targets and delivery methods of therapeutics are not well-known. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis. Disclosed herein are Etf-1-specific nanobodies (Nbs) that block Etf-1 functions and Ehrlichia infection. Also disclosed is a method for treating human monocytic ehrlichiosis (HME) in a subject with the disclosed nanobodies.
Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
Abstract: The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
November 1, 2022
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
October 25, 2022
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
October 11, 2022
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Bernhard Eckert, Michael Gerg, Johann Karl, Martin Kaufmann, Julia Riedlinger, Magdelena Swiatek-de Lange, Lars Hillringhaus, Klaus Hirzel, Marcus-Rene Lisy
Abstract: The application provides anti-PD-1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
October 11, 2022
Assignee:
SYSTIMMUNE, INC.
Inventors:
Brian Kovacevich, Dong Xia, Anne E. Jensen, Jonathan K. Fallen, Blair Renshaw, Jeffrey B. Adamo, Phil Tan, Zeren Gao, Yi Zhu
Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
Type:
Grant
Filed:
July 9, 2020
Date of Patent:
October 4, 2022
Assignees:
The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer, Inc.
Inventors:
Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
Type:
Grant
Filed:
March 16, 2017
Date of Patent:
October 4, 2022
Assignee:
Tillotts Pharm AG
Inventors:
Tea Gunde, Sebastian Meyer, Esther Maria Furrer
Abstract: Disclosed herein are chemotherapeutic methods for the treatment of cancer in humans. In at least one specific embodiment, the method can include administering a therapeutic effective amount of one or more p38 inhibitor compound or salt thereof to a human. The method can also include administering a therapeutic effective of one or more IL-6 inhibitor or one or more IL-6 receptor inhibitor or salt thereof to the human. The method can also include administering a therapeutic effective amount of one or more cytotoxic compound or salt thereof to the human.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
September 27, 2022
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands.
Type:
Grant
Filed:
December 4, 2015
Date of Patent:
September 27, 2022
Assignee:
XYPHOS BIOSCIENCES INC.
Inventors:
Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin
Abstract: Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.
Type:
Grant
Filed:
August 26, 2021
Date of Patent:
September 20, 2022
Assignee:
Iconic Therapeutics, Inc.
Inventors:
Jan-Willem Theunissen, Andrew D. Avery, II, Allen G. Cai, Anthony Byron Cooper, Thi-Sau Migone
Abstract: Disclosed are immunomodulatory polypeptides that behave as weak TLR2 and TLR4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine TLR2 and TLR4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
September 6, 2022
Assignees:
Chan Zuckerberg Biohub, Inc., The Board of Trustees of the Leland Stanford Junior University
Inventors:
Derek Croote, Stephen R. Quake, Kari Nadeau, Spyros Darmanis, David N. Cornfield